Leslie Phelps
Nurse Practitioner · Corbin, KYNPI 1598005654
Payments from drug & device makers
Across 104 payments — averaging $53.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optos, Inc.$4K
- AbbVie$828
- Gilead$91
- Braeburn Inc.$84
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$81
- Amgen$77
- plus $580 from 15 others
What the payments were for
- Speaking & faculty fees$3,81369%
- Food & beverage$1,70531%
- Education$361%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optos, Inc. | 1 | $3,813 |
| AbbVie | 53 | $828 |
| Gilead | 5 | $91 |
| Braeburn Inc. | 5 | $84 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $81 |
| Amgen | 3 | $77 |
| Grifols USA, LLC | 3 | $67 |
| GSK | 4 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Alkermes, Inc. | 3 | $53 |
| Lilly USA, LLC | 3 | $50 |
| Baxter Healthcare | 1 | $47 |
| Boehringer Ingelheim | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Indivior Inc. | 2 | $33 |
| AstraZeneca | 2 | $31 |
| Novo Nordisk | 2 | $30 |
| Resmed Corp | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
How this compares
$5,555 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 19 | $23,330 |
| MounjaroTirzepatide | 15 | $16,826 |
| JardianceEmpagliflozin | 27 | $15,544 |
| Nurtec OdtRimegepant Sulfate | 14 | $14,989 |
| LinzessLinaclotide | 21 | $11,431 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $10,082 |
| Repatha SureclickEvolocumab | 18 | $10,002 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $7,105 |
| FarxigaDapagliflozin Propanediol | 12 | $6,616 |
| SavellaMilnacipran Hcl | 13 | $6,259 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $5,162 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 54 | $4,421 |
| Ondansetron OdtOndansetron | 87 | $3,979 |
| Roflumilast | 33 | $3,675 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $3,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $30 | $23,33019 claims |
| AbbVieLinzess, Savella | $828 | $17,69034 claims |
| Lilly USA, LLCMounjaro | $50 | $16,82615 claims |
| Boehringer IngelheimJardiance | $40 | $15,54427 claims |
| AstraZenecaSymbicort, Farxiga | $31 | $13,72144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Corbin
- Whitney BartonCorbin$14K
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.